亿帆医药(002019.SZ)：N-3C01注射液获临床试验批准

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary Hefei Xinzhu Biotechnology Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of the innovative macromolecule drug N-3C01 injection, aimed at treating advanced solid tumors and non-muscle invasive bladder cancer (NMIBC) [1] Group 1 - The approval allows Hefei Xinzhu to conduct clinical trials for N-3C01 [1] - N-3C01 is positioned to address significant medical needs in the treatment of advanced solid tumors and NMIBC [1]